Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 1

Conditions

Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 2Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Mesalamine × Gastrointestinal × Clear all
NCT04920149 2024-12-17

MesaCAPP

Karolinska University Hospital

Phase 2 Recruiting
150 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis

NCT03070574 2019-04-18

MesaCAPP

Medical University of Vienna

Phase 2 Terminated
8 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02077777 2016-12-02

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

SOFAR S.p.A.

Phase 2 Completed
21 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡